Daphne Quimi
About Daphne Quimi
Daphne Quimi, age 59, has served as an independent director of Century Therapeutics (IPSC) since September 2022. She is Audit Committee Chair and a member of the Nominating & Corporate Governance Committee; her background includes CFO of Amicus Therapeutics (2019–Aug 2023), senior finance roles at Amicus (2007–2019), Bristol‑Myers Squibb, and Johnson & Johnson. She holds a B.S. in accountancy from Monmouth University, an MBA from NYU Stern, and is a New Jersey CPA .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Amicus Therapeutics, Inc. | Chief Financial Officer | Jan 2019 – Aug 2023 | Led public company finance; pay‑for‑performance perspective from CFO seat |
| Amicus Therapeutics, Inc. | SVP Finance & Corporate Controller | Sep 2007 – Feb 2019 | Oversaw public reporting, controls |
| Bristol‑Myers Squibb | Director of Consolidations & External Reporting | Prior to 2007 | SEC reporting expertise |
| Johnson & Johnson Services, Inc. | Finance roles (increasing responsibility) | May 1999 – Jul 2004 | Large‑cap finance and controls experience |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. | Director | Since Jul 2021 | Public biopharma board |
| Chiesi Group | Director | Since Jan 2025 | Global pharmaceutical company board |
Board Governance
- Independence: Board determined all non‑employee directors are independent; Quimi is listed as independent .
- Committee assignments: Audit Committee Chair; Nominating & Corporate Governance Committee member .
- Audit Committee: All members independent/financially literate; Butitta designated “audit committee financial expert”; remit includes oversight of external audit, internal controls, cybersecurity risk, related‑party transactions .
- Attendance: In 2024 the Board held seven meetings; each director attended ≥75% of Board and committee meetings; all directors attended the June 20, 2024 annual meeting .
- Leadership: Independent Chairman; CEO and Chair roles separated; independent committees and regular executive sessions without management .
Fixed Compensation
| Element | Amount | Notes |
|---|---|---|
| Member Annual Retainer (cash) | $40,000 | Paid quarterly in arrears |
| Chairperson Annual Retainer (cash) | $30,000 | Paid to Board Chair (separate from committee chairs) |
| Audit Chair Retainer (cash) | $15,000 | Committee chair fee |
| Compensation Chair Retainer (cash) | $10,000 | Committee chair fee |
| Nominating & Corporate Governance Chair Retainer (cash) | $8,000 | Committee chair fee |
| Audit Member Retainer (cash) | $7,500 | Committee member fee |
| Compensation Member Retainer (cash) | $5,000 | Committee member fee |
| Nominating & Corporate Governance Member Retainer (cash) | $4,000 | Committee member fee |
2024 Actuals (Director Compensation):
| Name | Fees Earned or Paid in Cash ($) | Option Awards – Grant Date Fair Value ($) | Total ($) |
|---|---|---|---|
| Daphne Quimi | 59,000 | 81,092 | 140,092 |
Performance Compensation
| Equity Award | Grant Size | Vesting Schedule | Notes |
|---|---|---|---|
| Initial Equity Grant (options) | 88,000 shares | Vests monthly over 36 months (time‑based) | Granted at commencement of director service under 2021 Plan |
| Annual Equity Retainer (options) | 44,000 shares | Vests in full on earlier of first anniversary or next annual meeting (time‑based) | Subject to continued service; granted after annual meeting |
Performance metrics tied to director compensation:
- None disclosed; non‑employee director equity grants are time‑based and not conditioned on financial/TSR or ESG metrics .
Grant timing and governance:
- Grants generally made following annual stockholder meetings for directors; committee observed no opportunistic timing relative to MNPI in 2024 .
Other Directorships & Interlocks
| Company | Overlap/Interlock | Potential Conflict Notes |
|---|---|---|
| Amylyx Pharmaceuticals, Inc. | None disclosed with IPSC vendors/customers | No related‑party transactions involving Quimi disclosed |
| Chiesi Group | Global pharma | No IPSC related‑party transactions with Chiesi disclosed |
Expertise & Qualifications
- Financial competency; decades of public company finance and reporting experience; former public company CFO .
- CPA (New Jersey); MBA (NYU Stern); B.S. in Accountancy (Monmouth) .
- Governance experience on multiple pharma boards; Audit Committee leadership at IPSC .
Equity Ownership
| Item | Amount |
|---|---|
| Common shares owned | 5,000 |
| Options exercisable within 60 days | 78,224 |
| Total beneficial ownership (as of Apr 15, 2025) | 83,224 |
| Ownership % of outstanding shares | <1% (“*” per proxy footnote) |
| Hedging/pledging of company stock | Prohibited by policy (no margin accounts, hedging, pledging) |
Insider Trades
| Filing Date | Form | Summary | Source |
|---|---|---|---|
| 2024-06-21 | Form 4 | Reported director option grant; vesting on earlier of June 20, 2025 or next annual meeting, subject to continued service | |
| 2025-06-16 | Form 4 | Reported changes in beneficial ownership (details in filing PDF) |
Governance Assessment
- Board effectiveness: Strong audit oversight with Quimi as Audit Chair; committee remit explicitly covers external audit, internal controls, cybersecurity risks, and related‑party transaction approvals; all committee members independent and financially literate .
- Independence and engagement: Independent director with ≥75% meeting attendance in 2024 and present at the 2024 annual meeting; board operates with independent chair and executive sessions, supporting objective oversight .
- Alignment: Beneficial ownership is <1% but includes exercisable options; director compensation includes time‑based options plus cash retainers; hedging and pledging prohibited, improving alignment and reducing conflict risk .
- Conflicts/related party exposure: No related‑party transactions disclosed involving Quimi; Audit Committee reviews and approves related‑party transactions per policy .
RED FLAGS: None disclosed specific to Daphne Quimi (no pledging, no related‑party transactions, attendance ≥75%, independent status) .